Science & Enterprise subscription

Follow us on Twitter

  • A company developing protein-like therapies for cancer from synthetic bacteria is being acquired by drug maker Sano… https://t.co/vSjgne2OIz
    about 3 hours ago
  • New post on Science and Enterprise: Synthetic Bio Company Acquired in $2.35B Deal https://t.co/cNWHszuo06 #Science #Business
    about 3 hours ago
  • That's very kind @GRC2001 ... Many thanks. Much appreciated. https://t.co/KNO7c6OnjM
    about 19 hours ago
  • Rice University and the energy company Shell launched a program to sustainably produce carbon derived from splittin… https://t.co/DnO3xbaYe7
    about 22 hours ago
  • New post on Science and Enterprise: Rice Univ, Shell Partner on Sustainable Carbon https://t.co/isa4P4VAve #Science #Business
    about 22 hours ago

Please share Science & Enterprise

Merck Gaining Gut Microbe Technology for Vaccines

Microbiome graphic

Drug maker Merck & Co. is partnering with a developer of treatments for disease derived from microbes in the gut, for discovery of up to three vaccines. . . . → Read More: Merck Gaining Gut Microbe Technology for Vaccines

Women-Founded Start-Ups Raise More Capital Than Male-Only

Median funds raised by round

Start-up enterprises founded or led by at least one woman on the team raise more capital than comparable start-ups founded by men only. . . . → Read More: Women-Founded Start-Ups Raise More Capital Than Male-Only

Start-Up Targets Extra DNA in Cancer, Raises $46.4M

Paul Mischel

A new biotechnology enterprise is developing treatments for aggressive solid tumor cancers that block the effects of DNA residing outside of chromosomes. . . . → Read More: Start-Up Targets Extra DNA in Cancer, Raises $46.4M

Migraine Drug Developer Raises $82.5M in IPO

NASDAQ share price display

A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO

Gene-Editing Biotech Gains $34M in Early Funds

Sickle cell illustration

A two year-old enterprise spun-off from Yale University is developing gene-editing treatments for genetic disorders with synthetic peptides and DNA delivered in nanoscale particles. . . . → Read More: Gene-Editing Biotech Gains $34M in Early Funds

Stanford, Berkeley, MIT Top Undergrad Start-Up Ranking

Shop open sign

Stanford University, University of California in Berkeley, and Massachusetts Institute of Technology lead the undergraduate programs producing founders of start-up companies in 2019. . . . → Read More: Stanford, Berkeley, MIT Top Undergrad Start-Up Ranking

Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Laptops on a table

Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group. . . . → Read More: Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Gates Investing in HIV, Tuberculosis Immunotherapies

T-cell infected by HIV

The Bill and Melinda Gates Foundation is taking an equity stake in a biotechnology company developing immunotherapies from messenger RNA. . . . → Read More: Gates Investing in HIV, Tuberculosis Immunotherapies

Aging Therapy Network Adds $100M to Venture Round

Hands on lap

An enterprise supporting a group of companies developing new drugs to address the aging process raised another $100 million in its second venture funding round. . . . → Read More: Aging Therapy Network Adds $100M to Venture Round

Infographic – A.I. Venture Deals Reach New Highs

AI funding chart

The total amount of venture capital worldwide raised by artificial intelligence start-up companies set a record in the second quarter of 2019, reaching $7.4 billion. . . . → Read More: Infographic – A.I. Venture Deals Reach New Highs